



MAR 29 2017

5.8

**Sylvia Jones, MPP**  
Dufferin-Caledon

Room 443, Legislative Building  
Toronto, Ontario M7A1A8

Tel: 416-325-1898  
Fax: 416-325-1936  
E-Mail: [sylvia.jonesla@pc.ola.org](mailto:sylvia.jonesla@pc.ola.org)

March 22<sup>nd</sup>, 2017

Chair Fred Eisenberger and Committee  
Hamilton Public Health Services  
110 King St. West, 2nd Floor  
Hamilton, ON  
L8P 4S6

Dear Chair Eisenberger and Committee,

I wanted to inform you of an exciting development regarding my private member's bill, *The Greater Access to Hepatitis C Treatment Act, 2016*. Bill 5 sought to ensure that every individual in Ontario with hepatitis C would receive treatment upon the recommendation from their physician, no matter the stage of their disease.

On February 21, 2017, the Ontario government announced the conclusion of negotiation through the pan-Canadian Pharmaceutical Alliance (pCPA). As a result of the pCPA agreement, Ontario expanded access to three already-funded hepatitis C treatments (Harvoni, Sovadi, Ibavyr) and added four new drugs (Epclusa, Zepatier, Daklinza and Sunverpra) to the ODB formulary. In addition, coverage will be extended to all patients regardless of severity of disease or genotype within the next 12 months.

I am pleased that the government has listened to the recommendation of the Canadian Agency for Drugs and Technologies (CADTH) and experts like you and adopted my proposal by announcing this important and overdue change. Thank you for your support in advocating for patients with hepatitis C.

Sincerely,

A handwritten signature in black ink, appearing to be "SJ", with a stylized flourish at the end.

Sylvia Jones, MPP  
Dufferin-Caledon  
Deputy Leader of the PC Caucus  
Progressive Conservative Critic for Infrastructure